We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

91 hedge funds and large institutions have $152M invested in Cascadian Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,900% more call options, than puts

Call options by funds: $50K | Put options by funds: $1K

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

15% more funds holding

Funds holding: 79 → 91 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less capital invested

Capital invested by funds: $166M → $152M (-$14.1M)

Holders
91
Holders Change
+12
Holders Change %
+15.19%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
30
Reduced
19
Closed
5
Calls
$50K
Puts
$1K
Net Calls
+$49K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.95M
2
ACA
Avoro Capital Advisors
New York
+$2.72M
3
PC
Polar Capital
United Kingdom
+$2.66M
4
Goldman Sachs
Goldman Sachs
New York
+$2.53M
5
KCM
Kennedy Capital Management
Missouri
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$12.3M
2
RG
Redmile Group
California
-$5.41M
3
Deutsche Bank
Deutsche Bank
Germany
-$1M
4
SKK
Shepherd Kaplan Krochuk
Massachusetts
-$170K
5
PAWC
P.A.W. Capital
Connecticut
-$164K
Name Holding Trade Value Shares
Change 		Change in
Stake
VFA
76
Valeo Financial Advisors
Indiana
$7K – – –
FDCDDQ
77
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.4K – – –
Royal Bank of Canada
78
Royal Bank of Canada
Ontario, Canada
$2K -$13.7K -3,355 -82%
Group One Trading
79
Group One Trading
Illinois
$2K -$29 -7 -1%
US Bancorp
80
US Bancorp
Minnesota
$2K +$2.03K +496 +24,800%
UBS Group
81
UBS Group
Switzerland
$1K -$6.04K -1,475 -83%
KF
82
Krilogy Financial
Missouri
$1K – – –
MOS
83
MGO One Seven
Ohio
$1K +$1.41K +344 New
EC
84
EcoR1 Capital
California
– -$12.3M -3,000,000 Closed
NFA
85
Nationwide Fund Advisors
Ohio
– -$90K -22,092 Closed
MWNA
86
Marshall Wace North America
New York
– -$54K -13,443 Closed
PAM
87
Panagora Asset Management
Massachusetts
– -$53K -12,868 Closed
ARTA
88
A.R.T. Advisors
New York
– -$44K -10,761 Closed
WCAMG
89
Woodard & Company Asset Management Group
North Carolina
– +$111 +27 New
GI
90
Gradient Investments
Minnesota
– +$180 +44 New
AG
91
Advisor Group
Arizona
– +$258 +63 +573%
Simplex Trading
92
Simplex Trading
Illinois
– +$888 +217 +21,700%
1 2 3
4

CASC Hedge Fund Activity: Q4 2017 in Review

91 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2017, worth a combined $152M — down 8.5% from $166M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CASC positions and 5 closed out — a net gain of 13 holders — while 30 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $2.95M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $12.3M sold.

  • 91 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2017, up from 79 in Q3 2017.
  • Funds reported $152M of Cascadian Therapeutics, Inc. stock for Q4 2017, down 8.5% quarter-over-quarter.
  • 18 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2017 and 5 closed out, a net change of +13 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q4 2017 was BlackRock, an estimated $2.95M added.
  • The largest Cascadian Therapeutics, Inc. seller in Q4 2017 was EcoR1 Capital, an estimated $12.3M sold.

Based on aggregated 13F filings for Q4 2017.